Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,329 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Treatment Period 2 Clear all
Completed Phase 2 Interventional Results available

Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)

NCT00935883
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Eculizumab, Saline
Drug
Lead sponsor
Philip J. Rosenfeld, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 17, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional

A Study of Brenipatide in Participants With Alcohol Use Disorder

NCT07219953
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
LY3537031, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
29
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

NCT03131895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
30 mg dexlansoprazole capsules manufactured at TOB, 30 mg dexlansoprazole capsules manufactured at TPC, 60 mg dexlansoprazole capsules manufactured at TOB, 60 mg dexlansoprazole capsules manufactured at TPC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

NCT06592339
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
MK-0616
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Not applicable Interventional Results available

Gait Modification Treatments for Knee Pathology

NCT03116230
View directory record Official record
Conditions
Knee Injuries, Knee Osteoarthritis
Interventions
Cutaneous Stimulation, Knee Sleeve
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 17, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional

A Digital Therapeutic Platform for Swallowing and Drooling Problems in Parkinson's

NCT04664634
View directory record Official record
Conditions
Dysphagia, Parkinson Disease
Interventions
Aria Sensor
Device
Lead sponsor
Northwestern University
Other
Eligibility
22 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).

NCT06159166
View directory record Official record
Conditions
NF1, Cutaneous Neurofibroma, Monotherapy
Interventions
Mirdametinib
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)

NCT02633956
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Obeticholic Acid, Atorvastatin, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
22
States / cities
Phoenix, Arizona • La Jolla, California • Rialto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Not applicable Interventional

Cognitive-Behavioral Bibliotherapy for the Treatment of Obsessive Compulsive Disorder in Children and Adolescents

NCT00690729
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Cognitive Behavioral Bibliotherapy, Cognitive Behavioral Therapy
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
8 Years to 18 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
4
States / cities
Hartford, Connecticut • Storrs, Connecticut • Waterbury, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants

NCT06574828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB091, Moxifloxacin, BIIB091-matched Placebo, Moxifloxacin-matched Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)

NCT06688045
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib, Itraconazole
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

NCT02963831
View directory record Official record
Conditions
Colorectal Cancer, Ovarian Cancer, Appendiceal Cancer
Interventions
ONCOS-102, Durvalumab, Cyclophosphamide
Biological · Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 17, 2026, 7:15 PM EDT
Terminated Phase 2 Interventional Results available

CD40L Antagonism in Rheumatoid Arthritis (RA)

NCT05306353
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

NCT02334501
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effects of an Isometric Loading Intervention on Lower Extremity Landing Biomechanics in Individuals With Patellar Tendinopathy

NCT03262181
View directory record Official record
Conditions
Tendinopathy
Interventions
Isometric Exercise, Sham Transcutaneous Electrical Nerve Stimulation
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years to 28 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

NCT01965353
View directory record Official record
Conditions
Multiple Myeloma in Relapse
Interventions
Panobinostat, Dexamethasone, Lenalidomide, Bortezomib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
4
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors

NCT04134728
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
GSK3196165 (Otilimab), Sarilumab, Placebo to GSK3196165/ Sarilumab, csDMARDs
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma

NCT00596154
View directory record Official record
Conditions
CNS Lymphoma, CNS Brain Cancer, Non-Hodgkin's Lymphoma
Interventions
Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 72 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

NCT04422431
View directory record Official record
Conditions
Wilson Disease
Interventions
Bis-Choline Tetrathiomolybdate
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Sacramento, California • Ann Arbor, Michigan • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Amlodipine Tablets Under Fed Conditions

NCT00601302
View directory record Official record
Conditions
Hypertension, Chronic Stable Angina, Vasospastic Angina
Interventions
Amlodipine
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 7:15 PM EDT
Withdrawn Phase 2Phase 3 Interventional

GetHealthy-OA: A Program to Improve Pain and Function for Patients With Knee Osteoarthritis, Obesity, and Depression

NCT05482672
View directory record Official record
Conditions
Knee Osteoarthritis, Obese, Depression
Interventions
Fisetin, GetHealthy-OA mind-body program, Placebo oral capsule, Health education booklet
Drug · Behavioral
Lead sponsor
Cale Andrew Jacobs, PhD
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.

NCT01995383
View directory record Official record
Conditions
Atherosclerosis
Interventions
LS followed by NS diet condition, NS followed by LS diet condition, Placebo, RO6836191
Other · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 4, 2016 · Synced Oct 17, 2026, 7:15 PM EDT
Completed Phase 4 Interventional Results available

The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD

NCT03081156
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Glycopyrrolate / Formoterol Inhaler vs Placebo Inhaler
Drug
Lead sponsor
William Stringer, md
Other
Eligibility
40 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 17, 2026, 7:15 PM EDT
Recruiting Not applicable Interventional

Accelerated Pulmonary Rehabilitation in the Preoperative Period

NCT06432972
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Lung Cancer
Interventions
Pulmonary Rehab
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 7:15 PM EDT